CSF1R and colorectal carcinoma: Ongoing trials are currently exploring the use of combination of Nivolumab and the anti-CSF1R antibody, Cabiralizumab, in solid tumors on the one hand, and the combinations of Durvalumab and the anti-CSF1R antibody, Pexidartinib, in CRC [238].